NeuBase Therapeutics, Inc.
NBSEDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted in 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NeuBase Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NeuBase Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Symetryx Corp | 10% Owner | 0 | Sep 18, 2023 | 0 |
| Stephan Dietrich A | Founder and CEO | 93,234 | Aug 4, 2023 | 0 |
| Branning Todd P. | Chief Financial Officer | 84,200 | Mar 17, 2023 | 0 |
| Goldstein Dov A MD | Director | – | Sep 12, 2022 | 0 |
| Prendergast Franklyn G | Director | – | Sep 12, 2022 | 0 |
| Richman Eric I | Director | 44,960 | Sep 12, 2022 | 0 |
| Ende Eric J | Director | – | Sep 12, 2022 | 0 |
| McDougall Gerald J | Director | – | Sep 12, 2022 | 0 |
| Mann William Roland | Chief Operating Officer | 11,200 | Apr 1, 2022 | 0 |
| Rojas-Caro Sandra | Chief Medical Officer | – | Jan 25, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2023 (view filing) | Sep 14-18 | 4 days | Symetryx Corp10% Owner | SSaleCommon Stock, Par Value $0.0001 per Share | −282.4K | $1.33 | −$375.6K | −100.0%0 after | 3 lots |
| Sep 11, 2023 (view filing) | Sep 7-11 | 4 days | Symetryx Corp10% Owner | SSaleCommon Stock, Par Value $0.0001 per Share | −207.1K | $1.63 | −$336.7K | −30.5%472.9K after | 3 lots |
| Sep 7, 2023 (view filing) | Sep 1 | 6 daysLate | Symetryx Corp10% Owner | PPurchaseCommon Stock, Par Value $0.0001 per Share | +61.1K | $0.98 | +$59.9K | +9.9%680.1K after | |
| Apr 1, 2022 (view filing) | Mar 30 | 2 days | Mann William RolandChief Operating Officer | PPurchase | +6.20K | $1.92 | +$11.9K | +124.0%11.2K after | |
| Mar 21, 2022 (view filing) | Mar 18 | 3 days | Branning Todd P.Chief Financial Officer | PPurchase | +10.0K | $1.81 | +$18.1K | +50.0%30.0K after | |
| Mar 18, 2022 (view filing) | Mar 16-17 | 2 days | Branning Todd P.Chief Financial Officer | PPurchase | +20.0K | $1.68 | +$33.6K | New position20.0K after | 2 lots |
| Mar 7, 2022 (view filing) | Mar 1-4 | 6 daysLate | Richman Eric IDirector | PPurchase | +3.88K | $1.64 | +$6.35K | +9.4%45.0K after | 3 lots |